172 related articles for article (PubMed ID: 26979246)
1. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
Lo Russo G; Imbimbo M; Garassino MC
Tumori; 2016 Jun; 2016(3):223-5. PubMed ID: 26979246
[TBL] [Abstract][Full Text] [Related]
2. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
3. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
Su C; Zhou F; Shen J; Zhao J; O'Brien M
Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
[TBL] [Abstract][Full Text] [Related]
4. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
5. Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Gandhi L
Clin Adv Hematol Oncol; 2018 Jul; 16(7):484-485. PubMed ID: 30067619
[No Abstract] [Full Text] [Related]
6. Update on systemic therapy of advanced non-small-cell lung cancer.
Cufer T; Knez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
[TBL] [Abstract][Full Text] [Related]
7. The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.
Ernani V; Steuer CE; Jahanzeb M
Annu Rev Med; 2017 Jan; 68():153-168. PubMed ID: 27618751
[TBL] [Abstract][Full Text] [Related]
8. [Personalized medicine in non-small-cell carcinoma].
Iwama E; Takayama K; Baba E; Nakanishi Y
Fukuoka Igaku Zasshi; 2014 Mar; 105(3):57-66. PubMed ID: 25000657
[No Abstract] [Full Text] [Related]
9. Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.
Gridelli C; Ascierto PA; Grossi F; Baldini E; Favaretto A; Garassino MC; Morabito A; Migliorino MR; Rossi A; de Marinis F
Curr Clin Pharmacol; 2018; 13(2):76-84. PubMed ID: 29992894
[TBL] [Abstract][Full Text] [Related]
10. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
13. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.
Remon J; Morán T; Reguart N; Majem M; Carcereny E; Lianes P
Cancer Treat Rev; 2014 Jul; 40(6):723-9. PubMed ID: 24759598
[TBL] [Abstract][Full Text] [Related]
14. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
15. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Costa DB
Lung Cancer; 2007 Aug; 57(2):251-2. PubMed ID: 17566601
[No Abstract] [Full Text] [Related]
16. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.
Capelletto E; Novello S; Scagliotti GV
Future Oncol; 2014 May; 10(6):1081-93. PubMed ID: 24941991
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer.
Malik PS; Jain D; Kumar L
Oncology; 2016; 91 Suppl 1():26-34. PubMed ID: 27462979
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
20. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Giuliani J; Martelli S; Remo A; Bonetti A
Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
